BOOST: a phase 3 trial of sorafenib vs . best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI